Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 8/20 | 0.55 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.55 |
| ▸ | HTR3B | O95264 | 4/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR7 | P34969 | 3/20 | 0.50 |
| ▸ | HTR2B | P41595 | 3/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772851 | 1.00 | HTR3A (0.55) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL1846343 | 0.98 | HTR3A (0.54) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL22533692 | 0.98 | HTR3A (0.54) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL31342345 | 0.94 | HTR3A (0.50) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6195611 | 0.87 | HTR3A (0.61) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL19385633 | 0.86 | HTR3A (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL24628365 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HTT | |
| SCHEMBL232523 | 0.83 | HTR3A (0.60) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL29831886 | 0.83 | HTR3A (0.60) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL1904530 | 0.81 | HTR3A (0.61) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | claimed |
| EP-4058145-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| EP-2051978-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | claimed |
| WO-2007136875-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | SOUTHERN RESEARCH INSTITUTE (US) | 2023-02-14 | — | — | US | disclosed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-4076423-A1 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-03-31 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| WO-2004080981-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2004-09-23 | — | — | WO | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003105853-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | HTR3A 447/4885HTR3E 715/4885HTR3B 797/4885 |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | OPRL1, ACHE, PNMT | HTR3A 150/4885HTR3E 509/4885HTR3B 108/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | HTR3A 7/4885HTR3E 40/4885HTR3B 13/4885 |
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | XDH, PNP, MAVS | HTR3A 1228/4885HTR3E 1177/4885HTR3B 664/4885 |
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | HTR3A 431/4885HTR3E 297/4885HTR3B 266/4885 |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | CRBN, IKZF1, IKZF3 | HTR3A 2232/4885HTR3E 3154/4885HTR3B 2912/4885 |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | HTR3A 990/4885HTR3E 1524/4885HTR3B 725/4885 |
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | TRPM5, TRPM6, TRPM2 | HTR3A 1583/4885HTR3E 1392/4885HTR3B 1025/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | HTR3A 447/4885HTR3E 715/4885HTR3B 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.